Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

1,230 enrolled

Dermatologic

Melanoma, Meningeal Neoplasms

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Phase 1 Active not recruiting

54 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

15 enrolled

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05902520 2026-01-08

ACT

Phase 1 Active not recruiting

18 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Lung Neoplasms, Melanoma, Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT01697527 2025-11-24

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Phase 2 Active not recruiting

6 enrolled

Tumor-Agnostic

Neoplasms

NCT01416831 2025-03-17

SBRT/IL-2

Phase 2 Active not recruiting

44 enrolled 12 charts

Dermatologic

Melanoma

NCT02306954 2025-03-10

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Phase 2 Active not recruiting

84 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04643574 2025-02-14

NeoTIL in Advanced Solid Tumors

Phase 1 Active not recruiting

42 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT03546426 2024-10-01

MESOVAX

Phase 1 Active not recruiting

18 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

NCT01883297 2024-09-05

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Recurrence

NCT03501381 2023-09-01

High Dose IL 2 and Entinostat in RCC

Phase 2 Active not recruiting

46 enrolled

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

FT819 in Subjects With B-cell Malignancies

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

ACT

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

SBRT/IL-2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

NeoTIL in Advanced Solid Tumors

MESOVAX

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

High Dose IL 2 and Entinostat in RCC